
Lyell Immunopharma (LYEL) Stock Forecast & Price Target
Lyell Immunopharma (LYEL) Analyst Ratings
Bulls say
Lyell Immunopharma Inc has shown a notable increase in liquidity, with cash, cash equivalents, and marketable securities rising to $320 million, bolstered by a private placement, which reflects a robust financial position for continued developmental activities. The company has established a strong competitive edge in the CAR-T market, particularly with its lead product candidate, LYL273, demonstrating promising durability outcomes and receiving favorable expert feedback, enhancing its probability of regulatory approval. Overall, Lyell's advancements in clinical efficacy, particularly in solid tumors, alongside solid financial reserves, position the company favorably for future growth and opportunities within the immunotherapy landscape.
Bears say
The analysis reveals a decline in research and development expenses for Lyell Immunopharma, setting a reduction to $28.2 million in the third quarter of 2025 compared to $34.9 million in the second quarter, indicating potential challenges in funding ongoing projects. Significant risks loom over the company’s ability to penetrate the CAR-T market effectively, particularly in non-Hodgkin lymphoma, alongside concerns regarding the efficacy and safety of their product candidates LYL797, LYL119, and LYL845. Moreover, without clear evidence of treatment durability and manageable toxicity in larger patient populations, the anticipated success of LYL273 as a standard-of-care therapy remains uncertain, casting doubt upon the company’s future prospects and market positioning.
This aggregate rating is based on analysts' research of Lyell Immunopharma and is not a guaranteed prediction by Public.com or investment advice.
Lyell Immunopharma (LYEL) Analyst Forecast & Price Prediction
Start investing in Lyell Immunopharma (LYEL)
Order type
Buy in
Order amount
Est. shares
0 shares